Northwest presses on with DCVax brain cancer trial
This article was originally published in Scrip
Northwest Biotherapeutics is pressing ahead with enrolment into its ongoing large Phase II study of its personalised immune therapy for brain cancer DCVax-Brain.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.